In my search to find info on vaccine effectiveness, I stumbled upon an article about Israel and the Pfizer vaccine. An interesting point I was unaware of is that Israel was able to get a larger share of the vaccine by paying more for it and by sharing data with Pfizer to help in their Phase IV study. They are now at about 35% of the population being injected. Not sure where our dealings stand with Israel but paying above market for the drug is something I don't believe we've factored in to any of our calculations.
Quote:
Israel secured its substantial stock by paying above market price and by striking a data-sharing deal with Pfizer.
Here's the Article:
https://www.timesofisrael.com/high-israel-con...nsmission/